These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1597 related articles for article (PubMed ID: 15199112)
1. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112 [TBL] [Abstract][Full Text] [Related]
2. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Massarweh S; Osborne CK; Creighton CJ; Qin L; Tsimelzon A; Huang S; Weiss H; Rimawi M; Schiff R Cancer Res; 2008 Feb; 68(3):826-33. PubMed ID: 18245484 [TBL] [Abstract][Full Text] [Related]
3. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Kurokawa H; Arteaga CL Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237 [TBL] [Abstract][Full Text] [Related]
5. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234 [TBL] [Abstract][Full Text] [Related]
6. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302 [TBL] [Abstract][Full Text] [Related]
7. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682 [TBL] [Abstract][Full Text] [Related]
8. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. Gutierrez MC; Detre S; Johnston S; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Dowsett M J Clin Oncol; 2005 Apr; 23(11):2469-76. PubMed ID: 15753463 [TBL] [Abstract][Full Text] [Related]
9. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137 [TBL] [Abstract][Full Text] [Related]
10. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Kurokawa H; Lenferink AE; Simpson JF; Pisacane PI; Sliwkowski MX; Forbes JT; Arteaga CL Cancer Res; 2000 Oct; 60(20):5887-94. PubMed ID: 11059787 [TBL] [Abstract][Full Text] [Related]
12. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells. Zhao W; Zhang Q; Kang X; Jin S; Lou C Biochem Biophys Res Commun; 2009 Mar; 380(3):699-704. PubMed ID: 19285025 [TBL] [Abstract][Full Text] [Related]
13. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808 [TBL] [Abstract][Full Text] [Related]
14. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500 [TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104 [TBL] [Abstract][Full Text] [Related]
16. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159 [TBL] [Abstract][Full Text] [Related]
17. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance. Takahashi M; Hayashida T; Okazaki H; Miyao K; Jinno H; Kitagawa Y Cancer Sci; 2014 Jun; 105(6):675-82. PubMed ID: 24698107 [TBL] [Abstract][Full Text] [Related]
18. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells. Kim J; Lee J; Kim C; Choi J; Kim A Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908 [TBL] [Abstract][Full Text] [Related]
19. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells. Sengupta S; Schiff R; Katzenellenbogen BS Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Morrison G; Fu X; Shea M; Nanda S; Giuliano M; Wang T; Klinowska T; Osborne CK; Rimawi MF; Schiff R Breast Cancer Res Treat; 2014 Apr; 144(2):263-72. PubMed ID: 24554387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]